OMVAX, INC.
Biotech · Private
Native outer membrane vesicle (NOMV) vaccine against Neisseria meningitidis serogroup B with genetically attenuated endotoxin and mutant FHbp antigens
- Grants
- $3.3M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 0 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A universal vaccine for the prevention of meningococcal meningitis in Africa | $299,970 | |
| Federal grant | Department of Health and Human Services · Phase II · A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1127 | Odyssey Therapeutics | — | $571M |
| 1128 | Moderna | — | $556M |
| 1129 | Mariana Oncology | — | — |
| 1130 | OMVAX, INC. | — | — |
| 1131 | Denali Therapeutics | — | $500M |
| 1132 | MS Biotech Holdings, Inc. | — | $59M |
| 1133 | PROLACTA BIOSCIENCE INC | — | $65M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Vaccination Against Neisseria Gonorrhoeaeapplication
- SARS-COV-2 Receptor Binding Domain In Native Outer Membrane Vesiclesapplication
- Compositions And Methods For Vaccination Against Neisseria Gonorrhoeaeapplication
- SARS-COV-2 Receptor Binding Domain In?native Outer Membrane Vesiclesapplication
- Compositions And Methods For Vaccination Against Neisseria Gonorrhoeaeapplication
- SARS-COV-2 Receptor Binding Domain In Native Outer Membrane Vesiclesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.